Cytokinetics pharmaceuticals stock
WebMar 7, 2024 · Cytokinetics (Nasdaq:CYTK) earnings and revenue forecasts, price targets, future return on equity. ... President & Director exercised options and sold US$333k worth of stock Aug 04. Cytokinetics GAAP EPS of -$0.23 beats by $0.81, revenue of $88.97M beats by $85.24M ... High growth companies in the Pharmaceuticals & Biotech industry. WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Our Vision Leadership …
Cytokinetics pharmaceuticals stock
Did you know?
WebFeb 17, 2024 · In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company’s shares closed … WebApr 6, 2024 · Company. Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and …
WebApr 11, 2024 · Discover historical prices for CYTK stock on Yahoo Finance. View daily, weekly or monthly format back to when Cytokinetics, Incorporated stock was issued. WebMar 31, 2024 · Cytokinetics' heart disease drug, aficamten, is a "crown jewel in terms of the pipeline", said Oppenheimer analyst Justin Kim, who expects it could bring more than $1 billion in peak sales from U ...
WebApr 13, 2024 · China Universal Asset Management Co. Ltd. trimmed its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 96.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.The institutional investor owned 961 shares of the biopharmaceutical … WebGet the latest Cytokinetics, Inc. (CYTK) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …
WebMar 6, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.
WebNov 8, 2024 · Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional $18.0 million aggregate principal amount of the notes in connection with the offering, solely to cover... cryptopolyWebApr 10, 2024 · Zacks Equity Research. April 10, 2024, 9:23 AM · 3 min read. It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated … crypto miner profitsWebNov 3, 2024 · Cytokinetics (CYTK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $0.95 per share a year ago. crypto miner rentalWebOct 27, 2024 · Blum acknowledges some CYTK stock investors are watching for a possible Cytokinetics buyout after Bristol Myers spent north of $13 billion to acquire MyoKardia … crypto miner salaryWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has … crypto miner removerWebCytokinetics Inc (CYTK) Stock Price Today, News, Quotes, FAQs and Fundamentals 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. CYTK Cytokinetics Inc 3,105 $33.36 $0.27 (0.80%) Today Sentiment 0.00% Message Vol. 42.11% Volume (M) 720,685.00 52-Wk High $55.80 52-Wk Low $33.37 About Feed … cryptopolymorphismeWebMar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference Apr 17, 2024 10:00 AM EDT Keyword Search Press Release Archive 1998-2005 Year 2024 Apr 11 2024 5:00 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART cryptopolitik and the darknet